Cox proportional hazards model of association between gemtuzumab and survival among racial-ethnic and cytogenetic subgroups
| Cytogenetic subgroup Race-ethnicity . | Event free survival HR (95% CI) . | Overall survival HR (95% CI) . |
|---|---|---|
| All cytogenetic groups | ||
| All patients | 0.84 (0.69-1.03) | 0.91 (0.71-1.16) |
| Black | 0.62 (0.38-1.03) | 0.57 (0.33-0.99) |
| Hispanic | 0.99 (0.63-1.55) | 0.94 (0.56-1.57) |
| WNH | 0.85 (0.66-1.10) | 1.01 (0.74-1.39) |
| KMT2Ar AML | ||
| All patients | 0.64 (0.43-0.95) | 0.78 (0.48-1.27) |
| Black | 0.67 (0.24-1.86) | 0.36 (0.12-1.06) |
| Hispanic | 0.42 (0.15-1.18) | 0.84 (0.25-2.81) |
| WNH | 0.60 (0.36-0.98) | 0.79 (0.42-1.46) |
| Core binding factor AML | ||
| All patients | 0.79 (0.50-1.24) | 1.00 (0.53-1.87) |
| Black | 0.30 (0.10-0.92) | 0.44 (0.12-1.64) |
| Hispanic | 1.66 (0.63-4.35) | 1.19 (0.40-3.54) |
| WNH | 0.75 (0.42-1.35) | 1.22 (0.47-3.22) |
| Cytogenetic subgroup Race-ethnicity . | Event free survival HR (95% CI) . | Overall survival HR (95% CI) . |
|---|---|---|
| All cytogenetic groups | ||
| All patients | 0.84 (0.69-1.03) | 0.91 (0.71-1.16) |
| Black | 0.62 (0.38-1.03) | 0.57 (0.33-0.99) |
| Hispanic | 0.99 (0.63-1.55) | 0.94 (0.56-1.57) |
| WNH | 0.85 (0.66-1.10) | 1.01 (0.74-1.39) |
| KMT2Ar AML | ||
| All patients | 0.64 (0.43-0.95) | 0.78 (0.48-1.27) |
| Black | 0.67 (0.24-1.86) | 0.36 (0.12-1.06) |
| Hispanic | 0.42 (0.15-1.18) | 0.84 (0.25-2.81) |
| WNH | 0.60 (0.36-0.98) | 0.79 (0.42-1.46) |
| Core binding factor AML | ||
| All patients | 0.79 (0.50-1.24) | 1.00 (0.53-1.87) |
| Black | 0.30 (0.10-0.92) | 0.44 (0.12-1.64) |
| Hispanic | 1.66 (0.63-4.35) | 1.19 (0.40-3.54) |
| WNH | 0.75 (0.42-1.35) | 1.22 (0.47-3.22) |
Statistically significant values are bolded.
WNH, White non-Hispanic